Federal contract award
75A50122C00047
CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AJ15 — GENERAL SCIENCE & TECHNOLOGY R&D SVCS; GENERAL SCIENCE & TECHNOLOGY; R&D FACILITIES & MAJ EQUIP |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $213.8M |
| Current contract value | $213.8M |
| Potential contract value / ceiling | $649.8M |
| Start date | Aug 29, 2022 |
| Current end date | Oct 1, 2028 |
| Potential end date | Aug 24, 2032 |
| Latest award activity | Jul 8, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 10 of 10 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 8, 2026 | P00009 | $2.4M | NO COST MOD TO EXTEND THE POP FOR CLIN0001 THROUGH AUGUST 28, 2031. EXERCISE AND FULLY FUND OPT CLIN0005B FOR THE PROCUREMENT OF 4,896 ORAL SUSPENSION TREATMENT COURSES IN THE AMOUNT OF $2,360,280.00. UPDATE G.1. CO. UPDATE G.3. CONTRACTOR'S POI |
| Apr 21, 2026 | P00008 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE UEI FROM JLLWGQX6LNA5 TO MUM1EGCDWZJ4. |
| Sep 5, 2025 | P00007 | $17.1M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0004B IN THE AMOUNT OF $17,104,200 FOR 40,000 TREATMENT COURSES OF ORAL SUSPENSION TEMBEXA AND UPDATED ARTICLE B.2.2 OPTIONS, TABLE 5. |
| Dec 12, 2024 | P00006 | $0 | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL - ADD 52.204-14 CLAUSE TO THE CONTRACT |
| Sep 19, 2024 | P00005 | $67.4M | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL |
| Mar 19, 2024 | P00004 | $0 | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL |
| Mar 29, 2023 | P00003 | $0 | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL |
| Dec 16, 2022 | P00002 | $0 | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL |
| Sep 8, 2022 | P00001 | $0 | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL |
| Aug 26, 2022 | 0 | $126.9M | CHIMERIX INC: AR&D FOR SMALLPOX ANTIVIRAL |
Estimated positioning window
Aug 24, 2031 – Feb 24, 2032
35/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 35/100. Available recorded signals: 30 points.
- Contract end 2032-08-24 (2123 days from calculation)
- +5 points
- 1 historical awards in this buyer and category group
- +0 points
- 10 recorded award transactions
- +10 points
- Latest award action: 2026-07-08
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.